Board member, Health-Holland
Hans Schikan is board member and former chairman a.i. of Health-Holland, the Dutch Top Sector for Life Sciences & Health. He brings more than 25 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During his leadership, Prosensa entered into a collaboration with GlaxoSmithKline, was listed on NASDAQ with a successful IPO in 2013 and was acquired by BioMarin early 2015 for up to USD 840 million. His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He serves on the board of a number of public and private biopharma companies in The Netherlands, Belgium, Sweden and Switzerland, partly as chairman of the board. Finally, Hans is involved in two Venture Capital firms and co-founder of Pharvaris.